Insiders · MREO

Daniel Shames

Director at Mereo BioPharma Group plc (MREO) since January 2024

Daniel Shames has filed 4 insider reports with the SEC since January 2024, as director at Mereo BioPharma Group plc (MREO). The latest filing, on February 27, 2026, reports grant or award at Mereo BioPharma Group plc (MREO).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Daniel Shames is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Mereo BioPharma Group plc logo
MREO
Mereo BioPharma Group plc
Directorsince January 2024$0.2893Feb 27, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Daniel Shames with

Other insiders at the same companies

Questions about Daniel Shames

What is Daniel Shames's role at Mereo BioPharma Group plc?
Daniel Shames reports to the SEC as director at Mereo BioPharma Group plc (MREO), according to the latest filing on February 27, 2026.
Has Daniel Shames bought or sold stock recently?
No open-market purchases or sales by Daniel Shames are on file. The filings report grant or award.
How do I get alerts when Daniel Shames files?
Follow Daniel Shames on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Daniel Shames (SEC CIK 0002005702). Totals count each trade once, skipping amendments whose original is on file, from Jan 2, 2024 on. View on SEC EDGAR